Phio Pharmaceuticals Insider Buys: Owner’s Steady Accumulation Signals Hidden Confidence in Cancer‑Immunotherapy Pipeline

Insider Buying at Phio Pharmaceuticals: A Quiet Signal of Confidence

Recent Form 4 filings from Phio Pharmaceuticals Corp. reveal a modest yet telling buying activity by owner Patricia A. Bradford. On September 24 2026, Bradford purchased 6,500 shares at $1.01 each—slightly above the closing price of $1.02. While the transaction size is small relative to the company’s market cap of $11.85 million, it follows a consistent pattern of incremental purchases over the past 18 months. In September 2026, she had already bought 12,000 shares on the 15th, bringing her holdings to 57,651 shares, and earlier in February and September 2025 she acquired 18,800 and 18,500 shares respectively. Each purchase has been executed at the market price (or near it), suggesting a strategy of gradual accumulation rather than opportunistic speculation.

Implications for Investors and Phio’s Outlook

From an investor’s standpoint, Bradford’s steady buying can be interpreted as a vote of confidence in Phio’s long‑term prospects. The company’s share price has been under pressure, with a 52‑week low of $0.813 and a yearly decline of 57 %. Yet the insider’s purchases, occurring even when the stock trades near or below its 52‑week low, imply that she believes the company’s valuation is temporarily depressed. This perception may be bolstered by Phio’s focus on cancer immunotherapy—a high‑growth niche within biotechnology—though the firm’s earnings ratio of –0.733 indicates current profitability challenges. If Bradford’s view is shared by other insiders—such as Chairman Robert J. Bitterman, who recently bought 2,000 shares at $1.03—there could be a broader belief that the company is poised for a rebound once clinical milestones or regulatory approvals materialize.

Profile of Patricia A. Bradford

Bradford’s transaction history shows a disciplined, incremental approach. Over the last year and a half, she has purchased a total of roughly 57,000 shares, averaging about 2,500 shares per transaction. Her buys have occurred at or near the prevailing market price, without any significant price discounts that might indicate a distressed or opportunistic purchase. Moreover, her holdings have grown steadily, suggesting a long‑term commitment rather than a short‑term trade. The lack of any selling activity in the same period further reinforces the view that she sees lasting value in Phio’s pipeline and management team.

Broader Insider Activity Context

The insider buying does not occur in isolation. On September 22, 2026, Chairman Robert J. Bitterman purchased 2,000 shares, and on September 11, 2026, CFO Lisa Cabott sold 12,888 shares. These movements indicate that while some executives are consolidating positions, others are divesting—perhaps to meet regulatory requirements or to rebalance portfolios. Nevertheless, the net effect of recent insider transactions is a modest increase in direct ownership among top management, which could signal confidence that may resonate with the market.

What Should Investors Watch?

1. Pipeline Milestones – Phio’s focus on cancer immunotherapy means that clinical trial outcomes will be a key driver of future valuation.
2. Regulatory Developments – FDA approvals or changes in reimbursement policies could unlock new revenue streams.
3. Insider Holdings – Continued purchasing by senior executives, even at low stock prices, may presage a future upside.
4. Valuation Metrics – With a negative P/E and a steep yearly decline, the stock remains undervalued relative to peers, presenting a potential entry point for value‑oriented investors.

In sum, Patricia A. Bradford’s recent purchases—though small in scale—are part of a broader insider buying trend that may signal optimism about Phio Pharmaceuticals’ future. For investors willing to navigate the current price volatility, the insider activity could be a subtle endorsement of the company’s long‑term strategy and a potential catalyst for a rebound once key milestones are achieved.